X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs PFIZER - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA PFIZER GSK PHARMA/
PFIZER
 
P/E (TTM) x 53.8 34.0 158.2% View Chart
P/BV x 10.7 5.4 198.5% View Chart
Dividend Yield % 2.7 0.6 425.8%  

Financials

 GSK PHARMA   PFIZER
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
PFIZER
Mar-18
GSK PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs2,7602,365 116.7%   
Low Rs2,0401,625 125.5%   
Sales per share (Unadj.) Rs339.0430.3 78.8%  
Earnings per share (Unadj.) Rs41.478.7 52.6%  
Cash flow per share (Unadj.) Rs45.993.2 49.3%  
Dividends per share (Unadj.) Rs35.0020.00 175.0%  
Dividend yield (eoy) %1.51.0 145.5%  
Book value per share (Unadj.) Rs242.9586.5 41.4%  
Shares outstanding (eoy) m84.7045.75 185.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.14.6 152.7%   
Avg P/E ratio x57.925.3 228.6%  
P/CF ratio (eoy) x52.321.4 244.2%  
Price / Book Value ratio x9.93.4 290.5%  
Dividend payout %84.525.4 332.6%   
Avg Mkt Cap Rs m203,28091,271 222.7%   
No. of employees `000NA2.6 0.0%   
Total wages/salary Rs m5,2343,143 166.5%   
Avg. sales/employee Rs ThNM7,484.8-  
Avg. wages/employee Rs ThNM1,195.0-  
Avg. net profit/employee Rs ThNM1,369.1-  
INCOME DATA
Net Sales Rs m28,71519,685 145.9%  
Other income Rs m5451,143 47.7%   
Total revenues Rs m29,26020,828 140.5%   
Gross profit Rs m5,0595,003 101.1%  
Depreciation Rs m380663 57.4%   
Interest Rs m24 47.6%   
Profit before tax Rs m5,2225,479 95.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,8921,878 100.7%   
Profit after tax Rs m3,5083,601 97.4%  
Gross profit margin %17.625.4 69.3%  
Effective tax rate %36.234.3 105.7%   
Net profit margin %12.218.3 66.8%  
BALANCE SHEET DATA
Current assets Rs m21,81524,167 90.3%   
Current liabilities Rs m15,9999,544 167.6%   
Net working cap to sales %20.374.3 27.3%  
Current ratio x1.42.5 53.9%  
Inventory Days Days6455 115.4%  
Debtors Days Days1929 65.1%  
Net fixed assets Rs m12,4759,514 131.1%   
Share capital Rs m847458 185.1%   
"Free" reserves Rs m19,72626,375 74.8%   
Net worth Rs m20,57326,832 76.7%   
Long term debt Rs m625 24.0%   
Total assets Rs m39,47536,900 107.0%  
Interest coverage x2,612.01,305.5 200.1%   
Debt to equity ratio x00 31.3%  
Sales to assets ratio x0.70.5 136.4%   
Return on assets %8.99.8 91.0%  
Return on equity %17.113.4 127.1%  
Return on capital %26.220.4 128.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56422 2,517.9%   
Fx outflow Rs m7,4291,489 499.0%   
Net fx Rs m-6,865-1,466 468.2%   
CASH FLOW
From Operations Rs m4,7283,318 142.5%  
From Investments Rs m-1,042-2,383 43.7%  
From Financial Activity Rs m-3,066-1,104 277.9%  
Net Cashflow Rs m620-169 -367.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 63.9 79.3%  
Indian inst/Mut Fund % 10.2 7.5 136.0%  
FIIs % 23.8 4.9 485.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 23.7 65.0%  
Shareholders   102,036 85,207 119.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   PLETHICO PHARMA  BIOCON   FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Higher; Realty Stocks Lead(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.6% while the Hang Seng is down 0.2%.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Apr 23, 2019 12:05 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS